jueves, 31 de mayo de 2018

NCI Drug Dictionary - National Cancer Institute | m/M/3

NCI Drug Dictionary - National Cancer Institute

National Cancer Institute

408 results found for: M
MYC-targeting siRNA DCR-MYC
A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis. Check for active clinical trials using this agent. (NCI Thesaurus)
(Other name for: mycophenolic acid)
(Other name for: magnesium hydroxide/aluminum hydroxide)
(Other name for: busulfan)
(Other name for: gemtuzumab ozogamicin)
(Other name for: idiotype-pulsed autologous dendritic cell vaccine APC8020)
(Other name for: gold sodium thiomalate)
(Other name for: mirabegron)

No hay comentarios:

Publicar un comentario